HighTide Therapeutics Inc. announced the completion of a Phase IIb clinical study of its investigational drug HTD1801 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The company reported that while the safety and tolerability of HTD1801 were consistent with previous studies, certain factors such as management of concomitant medications and patient compliance may have impacted the trial results. A post hoc analysis controlling for these confounding factors indicated a trend of therapeutic improvement with HTD1801 compared to placebo. HighTide Therapeutics stated that it will further evaluate its clinical development strategy for the MASH indication based on the overall data and regulatory feedback. The company cautioned that there is no guarantee HTD1801 will ultimately be successfully marketed. The announcement did not specify when or if the detailed study results will be presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12016059), on February 05, 2026, and is solely responsible for the information contained therein.